ALKEM Stock View

Alkem Laboratories Ltd
stock-view-header

₹ 4,647.9

icon -84.30 | -1.78
Market Cap ₹( Cr.)
555,726.20
Proj. P/E (x)
34.16
Proj. P/BV (x)
5.45
Proj. ROE (%)
16.96
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
128,160.59

Stock View

HOLD

Last Updated On.
26-Nov-2023
 

The average score for Alkem Laboratories Ltd stands at 8 against 6, three months back.

Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
3,882.81
100 DMA(₹)
3,825.96
200 DMA(₹)
3,579.51
52 Weeks Range
2,835.05     4,784.35

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required